SQI Diagnostics signs commercial contract with global biotech

18-Jul-2017 - Last updated on 19-Jul-2017 at 16:59 GMT

SQI develops custom research and diagnostic assays. (Image: iStock/JK1991)

SQI Diagnostics Inc. has signed an agreement to commercialize a custom multiplexed assay for a Waltham, MA-based global biotechnology company's blood disorder drug program.

As part of the agreement, SQI will provide sample analysis and data reporting services on human study samples using a custom-developed test unique to the unnamed customers biologic therapeutic.

Russell Peloquin, vice president, Global Commercial Operations at SQI Diagnostics told us the custom assay provider is excited to begin the commercial relationship with the company, with which they have not worked before.

“Contracts have been signed and a purchase order has been received,” he said. “We are now awaiting reagents from the customer that are scheduled to arrive shortly.”

Once the reagents are received, the company will complete its assay development processes and will begin receiving samples for analysis and reporting to the customer.

As a small company, Peloquin said it is constantly going head-to-head with incumbent platforms that have been around for years.

“As part of target customers’ vetting process, we are being measured against these older technologies,” he explained. However, as he said is demonstrated with the most recent commercial contract, Peloquin added, “the industry has gained enough confidence in not only our technology, but also in our unique and flexible business models to afford us credibility throughout the market.”